OBJECTIVES: To evaluate the diagnostic performances of four SARS-CoV-2 IgG antibody immunoassays.

METHODS: Following immunoassays were studied: Abbott's SARS-CoV-2 IgG assay, Diasorin's Liaison SARS-CoV-2 S2/S2 IgG assay, Euroimmun's Anti-SARS-CoV-2 IgG ELISA, and Roche's Elecsys Anti-SARS-CoV-2 assay. Specificity was retrospectively evaluated with 38 samples from 2019. Sensitivity samples (n = 147) were taken from SARS-CoV-2 real-time PCR-positive patients who developed COVID-19 symptoms ten days earlier.

RESULTS: Mean specificity was 96.6%. Mean sensitivity was 62.7% from ten days after onset of symptoms, 84.4% from 15 days after onset of symptoms, and 87.5% from 20 days after onset of symptoms.

CONCLUSIONS: Specificity was high, while Abbott and Roche were 100% specific. Sensitivity increased over time, with Abbott and Roche having the highest sensitivity at all time points with ≥90% from 20 days after symptoms' onset. These findings may assist in selecting SARS-CoV-2 IgG antibody immunoassays for additional diagnostics, epidemiological research, and vaccine development.

Original languageEnglish
Article number115313
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Issue number1
Early online date19 Jan 2021
Publication statusPublished - May 2021

Bibliographical note

Copyright © 2021 Elsevier Inc. All rights reserved.


  • COVID-19
  • IgG
  • Immunoassay
  • SARS-CoV-2
  • Sensitivity
  • Specificity

Fingerprint Dive into the research topics of 'Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays'. Together they form a unique fingerprint.

Cite this